Atezolizumab

Atezolizumab is a monoclonal antibody that selectively targets the programmed death-ligand 1 (PD-L1) protein. It is an immune checkpoint inhibitor, which means it helps the immune system recognize and attack cancer cells more effectively.
Atezolizumab is used for the treatment of various types of cancer, including non-small cell lung cancer, urothelial carcinoma, and triple-negative breast cancer. It is typically prescribed for patients whose tumors express PD-L1 and have not responded well to other treatments.
By blocking the interaction between PD-L1 and its receptor, PD-1, on T-cells, atezolizumab enhances the ability of the immune system to recognize and eliminate cancer cells. This treatment has shown promising results in clinical trials, improving overall survival rates and quality of life for patients with advanced-stage cancers.
However, be aware that atezolizumab can cause side effects, including fatigue, musculoskeletal pain, and infusion reactions. Patients should discuss the potential risks and benefits of this medication with their healthcare provider before starting treatment.